glp-1 news 2025 november ISPOR 2025: Exploring reasons for discontinuation Who Gets the Shot? GLP-1

The challenge is that you cant tell muscle vs

A treatment-related increase in benign thyroid C-cell adenomas was seen in males in 0.25 and 0.75 mg/kg/day liraglutide groups with incidences of 12%, 16%, 42%, and 46% and in all female liraglutide-treated groups with incidences of 10%, 27%, 33%, and 56% in 0 (control), 0.075, 0.25, and 0.75 mg/kg/day groups, respectively

Constant cravings

Any considerations outside of this age range would need to be specifically determined by a licensed clinician on a case-by-case basis

Early studies show promising results for alcohol use disorder, with several clinical trials now exploring applications for other substance dependencies

Plasma insulin-like growth factor 1 is associated with cognitive impairment in Parkinsons disease